Reply: Appropriate prospective trials are warranted to determine differences between exon 19 deletions and L858R EGFR mutations in non-small cell lung cancer

Ejemplares similares

• 3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma
  por: Liu, Guixue, et al.
  Publicado: (2020)
• Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
  por: Costa, D B, et al.
  Publicado: (2007)
• Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation
  por: Peng, Liang, et al.
  Publicado: (2015)
• The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer
  por: Zhang, Yaxiong, et al.
  Publicado: (2017)
• Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
  por: Batra, Ullas, et al.
  Publicado: (2023)